Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

H. G. Katz, Matthew; Shi, Qian; Meyers, Jeff; M. Herman, Joseph; D. Chuong, Michael; M. Wolpin, Brian; A. Ahmad, Syed; Marsh, Robert; Schwartz, Larry; C. Behr, Spencer; L. Frankel, Wendy; A. Collisson, Eric; L. Leenstra, James; M. Williams, Terence; M. Vaccaro, Gina; P. Venook, Alan; A. Meyerhardt, Jeffrey; M. O’Reilly, Eileen

doi:10.1001/jamaoncol.2022.2319

Public

Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

Published in JAMA Oncology • Jul 14, 2022

Authors:

Matthew H. G. Katz

Qian Shi

Jeff Meyers

Abstract

Importance: National guidelines endorse treatment with neoadjuvant therapy for borderline resectable pancreatic ductal adenocarcinoma (PDAC), but the optimal strategy remains unclear. Objective: To compare treatment with neoadjuvant modified FOLFIRINOX (mFOLFIRINOX) with or without hypofractionated ...

Subject

Medicine

FOLFIRINOX

Interim analysis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!